

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with MCI or early AD in the general population

Jacqueline J. Claus^{1,2}, Ilse vom Hofe¹, Anneke van Ijzenga Veenstra¹, Silvan Licher^{1,3}, Harro Seelaar⁴, Frank J. de Jong⁴, Julia Neitzel^{1,2}, Meike W. Vernooij^{1,2}, M. Arfan Ikram¹, Frank J. Wolters^{1,2}

1. Dept. of Epidemiology, Erasmus MC, Rotterdam, the Netherlands
2. Dept. of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands
3. Dept. of General Practice, Erasmus MC, Rotterdam, the Netherlands
4. Dept. of Neurology, Erasmus MC, Rotterdam, the Netherlands

Corresponding Author:

Frank J. Wolters, MD, PhD

Department of Epidemiology, Erasmus MC

PO Box 2040, Rotterdam 3000CA, the Netherlands

Tel +31 10 7043488, Email: f.j.wolters@erasmusmc.nl

Key words: amyloid, clinical trials, monoclonal antibodies, Alzheimer's disease, generalizability

Manuscript: 3,529

Title: 21

Abstract: 358

References: 37

Figures: 4

Tables: 2

Supplementary tables: 7

Supplementary

figures:

1

1

1 **Abstract**

2 **Background**

3 Treatment with monoclonal antibodies against amyloid- β slowed cognitive decline in recent randomized
4 clinical trials in patients with mild cognitive impairment (MCI) and early dementia due to Alzheimer's
5 disease (AD). However, stringent trial eligibility criteria may affect generalizability of these findings to
6 clinical practice.

7
8 **Methods**

9 We extracted eligibility criteria for trials of aducanumab, lecanemab and donanemab from published
10 reports, and applied these to participants with MCI or early clinical AD dementia from the population-
11 based Rotterdam Study. Participants underwent questionnaires, genotyping, brain MRI, cognitive testing,
12 and cardiovascular assessment. We had continuous linkage with medical records and pharmacy
13 dispensary data. We determined amyloid status using an established and validated prediction model
14 based on age and *APOE* genotype. We assessed progression to dementia within 5 years among
15 participants with MCI, stratified for eligibility.

16
17 **Results**

18 Of 968 participants (mean age: 75 years, 56% women), 779 had MCI and 189 early clinical AD dementia.
19 Across the three drug trials, around 40% of participants would be ineligible because of predicted amyloid
20 negativity. At least one clinical exclusion criterion was present in 76.3% (95% CI; 73.3-79.3) of
21 participants for aducanumab, 75.8% (73.0-78.7) for lecanemab, and 59.8% (56.4-63.3) for donanemab.
22 Criteria that most often led to exclusion were a history of cardiovascular disease (35.2%), use of
23 anticoagulant (31.2%), use of psychotropic or immunological medications (20.4%), history of anxiety or
24 depression (15.9%), or lack of social support (15.6%). One-third of participants were ineligible based on
25 brain MRI findings alone, which was similar across trials and due predominantly to various
26 manifestations of cerebral small-vessel disease. Combining amyloid, clinical, and imaging criteria,
27 eligibility ranged from 9% (7.0-11.1) for aducanumab, 8% (6.2-9.9) lecanemab to 15% (12.4-17.5) for
28 donanemab. Risk of progression to dementia tended to be higher for ineligible than for eligible
29 participants for lecanemab (hazard ratio [95%CI]: 1.64 [0.92-2.91]), aducanumab (HR: 1.17 [0.65-2.12]),
30 and only marginally for donanemab (HR: 1.03 [0.67-1.59]).

31
32 **Conclusions**

33 Findings from recent RCTs reporting protective effects of monoclonal antibodies against amyloid- β are
34 applicable to less than 15% of community-dwelling individuals with MCI or early AD. These findings
35 underline that evidence for drug efficacy and safety is lacking for the vast majority of patients with
36 MCI/AD in routine clinical practice.

37 Introduction

38 Alzheimer's disease (AD) is the leading cause of dementia, contributing to 38 million cases worldwide.¹
39 The search for disease modifying therapy against AD has long been fruitless, with disappointing results
40 from various trials aimed predominantly at the removal of cerebral β -amyloid depositions.² Since 2021,
41 however, three randomized clinical trials of monoclonal antibodies against β -amyloid have shown
42 slowing of cognitive and functional decline in patients with mild cognitive impairment (MCI) and early-
43 stage AD dementia.³⁻⁵ This led to the conditional approval of aducanumab (June 2021) and regular
44 approval of lecanemab by the United States Food and Drug Administration (FDA, July 2023) and the
45 Japanese New Drug Application (September 2023) as the first disease-modifying therapies.⁶⁻⁸
46 Donanemab has been filed for approval, and a decision by the European Medical Association (EMA) on
47 lecanemab is pending.^{9,10} The approval of these monoclonal antibodies against β -amyloid for clinical use
48 raises the question to which extent findings from trials are generalizable to the wider patient population,
49 in terms of both efficacy and safety.¹¹

50
51 With regard to efficacy, external validity is of particular relevance for trials against AD, as dementia in the
52 general population is often due to mixed pathology, and roughly half of the explained variance in clinical
53 syndromes of AD dementia is not due to AD-related pathological indices.¹² Efficacy in patients with pure
54 AD may not apply to patients with comorbid pathology, if the latter did not take part in clinical trials.
55 Indeed, trial eligibility criteria for AD trials preclude certain groups of patients, with criteria ranging from
56 restrictions in age to various types of comorbidities, medication use, and evidence of vascular brain
57 injury on magnetic resonance imaging (MRI). Similarly for safety, restriction of trial enrolment to patients
58 with relatively little comorbidity may underestimate occurrence of adverse effects, like amyloid-related
59 imaging abnormalities (ARIA), in the patient population seen in routine practice.

60
61 Three studies have thus far investigated external validity of Alzheimer trials in specialised memory clinic
62 populations. Applying eligibility criteria of aducanumab and lecanemab to these patient populations in
63 Italy and Ireland, 73-99% of participants would have been ineligible for trial inclusion.¹³⁻¹⁵ Similarly, two
64 studies using medical claims data in the United States of America found that over 90% would have been
65 excluded from participation in trials of amyloid-lowering therapy.^{16,17} Population-representative data of
66 European patients are lacking. Moreover, the largest clinical benefit to date has been observed for
67 donanemab in the TRAILBLAZER-ALZ2 trial, but no published studies have yet examined the impact of
68 donanemab trial eligibility on external validity in the general population with MCI and AD dementia.⁵

69

70 In this study, we aimed to assess generalizability of trials of efficacious amyloid-lowering drugs by
71 applying trial eligibility criteria to participants with MCI and early dementia due to AD in the population-
72 based Rotterdam Study.

73

74 **Methods**

75 *Selection of Trials*

76 On august 14th 2023, we searched the literature for published phase 3 trials of monoclonal antibodies
77 against β -amyloid that met their primary outcome for reducing cognitive and functional decline. Trials
78 included were EMERGE (the high-dose arm of aducanumab), CLARITY-AD (lecanemab), and
79 TRAILBLAZER-ALZ2 (donanemab). Details of included trials are presented in Supplementary Table 1. Trial
80 inclusion and exclusion criteria were obtained from ClinicalTrials.gov and the original trial publications.³⁻⁵
81 In case of discrepancy between ClinicalTrials.gov and the published report, we selected criteria from the
82 latter.

83

84 *Study Population to assess generalizability of trial findings*

85 The Rotterdam Study is an ongoing population-based cohort study investigating determinants and
86 occurrence of disease in persons aged 40 years and older. The study started in 1990 and now comprises
87 17,931 individuals living in the Ommoord suburb of Rotterdam, the Netherlands. The design of the
88 Rotterdam Study has been described in detail previously.¹⁸ In brief, participants are invited for interview
89 and extensive in-person examination at a dedicated research centre every 3-6 years. Routine
90 examinations as part of the Rotterdam Study protocol include standardised questionnaires (e.g., social
91 support, mental health, medication use), cognitive assessment, cardiovascular exams (e.g., blood
92 pressure measurement, electrocardiogram and cardiac ultrasound), psychiatric assessment,
93 venepuncture, and genotyping. From 2005 onward, brain MRI became part of the core study protocol of
94 the Rotterdam Study. For the current study, we included all 968 participants who were diagnosed with
95 MCI (n=779) or early dementia due to clinical manifestation of AD (n=189) during the fourth (2002-2005)
96 and fifth (2009-2013) examination cycle of the study. Participants with dementia included in the current
97 study had to have a dementia diagnosis within 1 year from their study centre visit. From 2005 onwards
98 MRI of the brain was implemented into the core protocol of the Rotterdam Study. In total, 255/454
99 participants with MCI or early dementia due to AD from the fifth examination round had brain MRI scan
100 available.

101 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus
102 Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the
103 Population Studies Act for the Rotterdam Study. All participants provided written informed consent for
104 participation in the study, including permission to obtain information from their treating physicians.

105

106 *Ascertainment of mild cognitive impairment and dementia*

107 Participants were screened for dementia at baseline and every 3-6 years during follow-up examinations
108 using the Mini-Mental State Examination (MMSE) and the Geriatric Mental Schedule (GMS) organic level.
109 Those with a MMSE score of <26 or a GMS organic level score of >0 were further examined using the
110 Cambridge Examination for Mental Disorders of the Elderly . Additionally, participants were continuously
111 under surveillance for incident dementia through the electronic linkage between the study database and
112 medical records from general practitioners and the Regional Institute of Outpatients Mental Health Care.
113 The general practitioner functions as a gatekeeper within the Dutch healthcare system, receiving written
114 information of any medical specialists' consultations of their patients. The final diagnosis of dementia
115 and its most common subtypes was made by a consensus panel led by a neurologist based on the
116 standard criteria for all-cause dementia (DSM-III-R) and clinical Alzheimer's disease (NINCDS-ADRDA).
117 Follow-up for dementia was completed until January 1, 2020.

118 Criteria for MCI were based on the Petersen criteria, and included the presence of subjective
119 cognitive complaints and objective cognitive impairment, in the absence of dementia.¹⁹ A detailed
120 description of our MCI assessment has been published previously.²⁰ Subjective cognitive complaints
121 were evaluated by interview, including questions on memory and everyday functioning. We assessed
122 objective cognitive impairment using a cognitive test battery comprising the letter-digit substitution task,
123 Stroop test, verbal fluency test (animal categories), and 15-word verbal learning test based on Rey's
124 recall of words.²¹ Compound scores were constructed for various cognitive domains, including memory
125 function, information-processing speed, and executive function.^{21,22} We classified persons as objectively
126 cognitively impaired if in any of the cognitive domains, the compound score was at least 1.5 standard
127 deviation lower than expected based on age and education adjusted means, derived from the study
128 population.

129

130 *Operationalization of Trial Eligibility Criteria*

131 For each of the trial inclusion and exclusion criteria, we defined an operationalization in the Rotterdam
132 Study. This was done through consensus discussion between two authors (JJC and FJW). A detailed
133 description of the eligibility criteria for each of the three trials, and their operationalization, is provided
134 in Supplementary Tables 2, 3 and 4. For example, history of cardiovascular disease was based on a
135 combination in-person assessment and continuous linkage with medical records for various

136 comorbidities, use of medication was assessed based on pharmacy dispensary data (ATC-codes), and we
137 had in-person questionnaires for social support and screening for anxiety and depression.

138

139 *Brain magnetic resonance imaging*

140 Participants underwent scanning on a 1.5-T MRI scanner (GE Healthcare) using a multisequence protocol
141 consisting of T1-weighted, proton density-weighted, fluid-attenuated inversion recovery, and T2-
142 weighted sequences. For brain volumetry, T1-weighted (voxel size $0.49 \times 0.49 \times 1.6 \text{ mm}^3$), proton
143 density-weighted (voxel size $0.6 \times 0.98 \times 1.6 \text{ mm}^3$), and the fluid-attenuated inversion recovery (FLAIR)
144 (voxel size $0.78 \times 1.12 \times 2.5 \text{ mm}^3$) scans were used for automated segmentation of brain tissues,
145 including white matter hyperintensities.^{23,24} In short, a k-nearest neighbor tissue classification algorithm
146 was implemented for quantification of white matter hyperintensities (WMH).²⁴ All segmentations were
147 visually inspected, and manually corrected if needed. Severe WMH were defined as a volume of 16.1
148 milliliter or more, corresponding to a Fazekas score of 3.^{25,26} All scans were appraised by trained research
149 physicians for the presence of cerebral microbleeds (i.e., small round to ovoid hypointense areas on T2*-
150 weighted images), lacunes (i.e., focal cavitating lesions ≥ 3 and $< 15 \text{ mm}$), and cortical infarcts.²⁷ These
151 ratings were done blinded to clinical data. Furthermore, abnormalities including superficial siderosis,
152 intracranial aneurysms, meningioma, suspected gliomas, cavernous angioma, arachnoid cysts,
153 arteriovenous malformations and dural fistulas were rated by research physicians, and subsequently
154 evaluated by a consultant neuroradiologist.

155

156 *Prediction of amyloid status*

157 To assess amyloid positivity, we used a prediction model based on age and *APOE* $\epsilon 4$ allele count.²⁸ This
158 model was developed within the Anti-Amyloid Treatment in Asymptomatic Alzheimer's trial population
159 (A4 Study), and previously showed high discriminative ability to differentiate people with and without
160 brain amyloid as measured by ¹⁸F-florbetaben PET in the Rotterdam Study population (area under the
161 curve: 0.84 [0.79–0.88]).²⁸

162

163 *Statistical analyses*

164 Missing data, most notably for social support (17.9%), Parkinson's disease (due to incomplete
165 assessment of the Unified Parkinson Disease Rating Scale, 7.0%) and anxiety disorder (9.1%), were
166 imputed using 5-fold multiple imputations ("mice" package in R). Details of all imputed variables are
167 described in supplementary table 7.

168 For each trial, we determined the number of participants who met the eligibility criteria, both
169 overall and per criterion separately. We compared the subset of trial eligible individuals to all individuals
170 with MCI and early AD dementia in the population on several key demographics and participant
171 characteristics, including, age, sex, educational attainment, MMSE, *APOE* ϵ 4 carrier status, MCI or
172 dementia status, cardiovascular disease and antithrombotic medication use. We repeated all analyses in
173 the subsample (n=255) with brain MRI.

174 Finally, among all individuals with MCI in the primary analyses, we determined 5-year
175 progression to dementia stratified by trial eligibility, by computing hazard ratios (HR) using Cox
176 proportional hazard models.

177 All analyses were performed in R (version 4.2.1). This study is reported according to the
178 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.²⁹

179 **Results**

180 *Study population*

181 Overall, 968 participants were diagnosed with MCI or early dementia (mean age 75.1 years, 55.2%
182 women), of whom 779 (80.5%) had MCI and 189 (19.5%) clinical AD dementia. Of these, trial-specific
183 entry scores on the MMSE were met by 751 (77.6%) participants for aducanumab (MMSE ≥ 24), 856
184 (88.4%) for lecanemab (MMSE ≥ 22) and 762 (78.7%) for donanemab (MMSE 22-28). Mean (\pm SD) age of
185 MMSE-eligible participants was similar across trials, varying from 74.0 (± 8.0) years for aducanumab, to
186 74.5 (± 8.1) for lecanemab and 75.3 (± 8.1) years for donanemab. Little over half of participants were
187 women for all three trials (51.6-55.6%).

188

189 *Trial eligibility criteria*

190 Trial eligibility criteria for EMERGE (aducanumab), CLARITY-AD (lecanemab), and TRAILBLAZER-ALZ2
191 (donanemab) are listed in supplementary tables 2, 3 and 4. Overall, TRAILBLAZER-ALZ2 listed the fewest
192 exclusion criteria. EMERGE was the only trial to exclude persons using platelet inhibiting or anticoagulant
193 medication. CLARITY-AD only included patients with objective impairment in episodic memory, whereas
194 the other two trials did not specify the affected cognitive domain among their inclusion criteria. All trials
195 excluded patients with severe small vessel disease on brain MRI (i.e., severe white matter
196 hyperintensities or >4 microbleeds). EMERGE and CLARITY-AD additionally excluded patients with
197 lacunes or cortical infarct. CLARITY-AD further excluded individuals with intracranial aneurysms,
198 meningioma, cavernous angioma, and arachnoid cysts. A potentially eligible participant has to go
199 through eight different modalities, including cognitive testing, assessment of prior medical history and
200 comedication, BMI measurement, venepuncture, blood pressure measurement, electrocardiogram,
201 brain MRI scan and amyloid-PET scan or lumbar puncture, as well as have an informant/care partner
202 present for the duration of the study.

203

204 *Eligibility on the basis of clinical criteria*

205 Around two-thirds of participants met at least one clinical exclusion criterion, somewhat higher for
206 aducanumab (76.3%; 95% CI 73.3-79.3) and lecanemab (75.8%; 73.0-78.7) than for donanemab (59.8%;
207 56.4-63.3) (Figure 1, Supplementary Table 5). Compared to all individuals with MCI and early AD
208 dementia in the Rotterdam Study, eligible participants were similar with respect to age, sex, educational
209 attainment, *APOE* $\epsilon 4$ carrier status (Table 1). MMSE scores at diagnosis were also similar between
210 groups, although eligible participants were slightly more often at the MCI stage rather than having early

211 dementia. Those eligible for donanemab had more cardiovascular disease (18.3%) compared to those
212 eligible for donanemab (16.4%) and aducanumab (10.1%).

213
214 Overall, exclusion criteria related to cardiovascular comorbidity had the largest effect on trial eligibility,
215 but its impact differed between trials (Table 1 and Figure 1). For aducanumab, 264/751 (35.2%)
216 participants were excluded because of cardiovascular disease, and 234/751 (31.2%, mostly overlapping)
217 due to use of anticoagulant medication. Cardiovascular disease amounted to 10.7% exclusion of
218 participants for lecanemab and 9.7% for donanemab. Neurological comorbidity and lack of social
219 support were common reasons for ineligibility across trials, affecting 13.2 to 15.6% of potential
220 participants. In trials of lecanemab and donanemab, 16% of people were ineligible based on indication
221 of presence of mental health disorders, due chiefly to positive screening for depression or anxiety
222 disorder. Psychotropic or immunological medication use frequently led to exclusions for aducanumab
223 (20.4%), while for lecanemab only 0.8% met trial-specific exclusions for immunological medication, and
224 donanemab had no such exclusions.

225
226 Figure 3 shows the overlap between the different exclusion criteria within participants. Around one third
227 of exclusion criteria across trials occurred in isolation (34% aducanumab, 41% lecanemab, 38%
228 donanemab), as illustrated by the single, unconnected dots in Figure 3. Two thirds of participants who
229 were ineligible due to cardiovascular disease also met one or multiple other exclusion criteria, similar
230 across trials (Figure 3). A notable exception is the presence of non-amnesic MCI (in the absence of
231 memory impairment), which was a common exclusion criterion for lecanemab (391/856, 45.2%), and
232 occurred in isolation in over half of participants meeting this criterion (202/391; 51.7%) (Figure 3).

233
234 *Impact of (predicted) amyloid positivity*

235 Amyloid status was predicted negative in around 40% of all participants with MCI and early clinical AD
236 dementia, similar across trials (aducanumab 42.3%, lecanemab 40.4%, donanemab 37.9%). When adding
237 amyloid negativity to the aforementioned clinical eligibility criteria, the percentage of persons who were
238 ineligible increased from 76.3 to 88.4% for aducanumab, from 75.8 to 86.0% for lecanemab, and from
239 62.3 to 76.4% for donanemab. Conversely, among all age and MMSE eligible Rotterdam Study
240 participants with positive predicted amyloid status, application of clinical exclusion criteria left 73.8% of
241 participants ineligible for aducanumab, 78.2% for lecanemab, and 49.5% ineligible for donanemab
242 (Figure 2 and Supplementary Table 6).

243

244 *MRI criteria*

245 Of all 968 included participants, 255 had an available brain MRI scan close to MCI/early AD diagnosis
246 (mean interval: 2.3 years). The most common imaging abnormalities were of presumed vascular nature,
247 with severe white matter hyperintensities in 24.6%, cortical infarcts in 10.6%, ≥ 2 lacunes in 7.5%, and >4
248 microbleeds in 3.1% of participants. Around one third of participants would be ineligible for trial
249 participation on the basis of imaging criteria alone, which was similar across trials (Figure 4).

250

251 Eligibility based on clinical criteria was similar in the MRI subsample compared to the overall sample.
252 Compared to the entire sample, participants who were eligible based on clinical and MRI criteria were
253 slightly younger, less educated and more often carrier of the *APOE* $\epsilon 4$ allele (Table 2). A combination of
254 all clinical criteria, MRI criteria, and predicted amyloid negativity resulted in trial ineligibility of 91.1%
255 (95% CI, 88.9-93.0) for aducanumab, 91.6% (90.1-93.8) for lecanemab and 85.2% (82.5-87.6) for
256 donanemab.

257

258 *Dementia progression*

259 During 5-year follow-up, progression to dementia was observed in 91 Rotterdam Study participants with
260 MCI. Participants with MCI who were ineligible based on clinical criteria tended to have higher risk of
261 progressing to dementia than eligible participants for lecanemab (HR: 1.64, 95% CI: 0.92 – 2.91),
262 aducanumab (HR: 1.17, 95% CI: 0.65 – 2.12) and only marginally for donanemab (HR: 1.03, 95% CI: 0.67
263 – 1.59).

264 **Discussion**

265 In this population-based study, findings from recent RCTs of monoclonal antibodies against amyloid- β are
266 applicable to less than 15% of persons with MCI and early clinical AD dementia. This percentage was
267 somewhat higher for donanemab (15%) than for aducanumab and lecanemab (8-9%). Trial ineligibility
268 was commonly due to comorbid vascular pathology, either clinically or on brain MRI, neurological or
269 psychiatric comorbidity, lack of social support, and concurrent anticoagulant or psychotropic medication
270 use.

271
272 Thus far, no published studies have assessed eligibility criteria for the TRAILBLAZER-ALZ2 trial of
273 donanemab, which had somewhat less stringent criteria compared to aducanumab and lecanemab.
274 Eligibility for donanemab is slightly higher compared to aducanumab and lecanemab, due to more liberal
275 inclusion of patients with cardiovascular comorbidity, but still limited at 15%. The observed eligibility of
276 around 10% for aducanumab and lecanemab in this population-representative European sample is in
277 accordance with two previous population-based studies from the United States.^{16,17} Clinic-based studies
278 from Italy and Ireland reported eligibility between 1% and 27%.¹³⁻¹⁵

279 Ineligibility in our study, as in previous reports, was mainly due to comorbid cardiovascular and
280 cerebrovascular disease.^{16,17} The limited inclusion of patients with vascular comorbidity underlines the
281 need for caution and careful monitoring of drug safety if prescribing anti-amyloid- β antibodies to a yet
282 untested patient population. Moreover, in patients with a combination of AD and vascular disease,
283 cognitive impairment is often in part a consequence of cerebrovascular pathology,³⁰ and observed
284 efficacy of monoclonal antibodies against amyloid- β in patients with relatively pure AD may not apply to
285 those individuals.

286
287 Stringent eligibility criteria in AD trials serve in part to reduce safety and tolerability concerns.¹⁵ Patients
288 excluded from clinical trials, particularly those with cardiovascular comorbidity, may face a conceivably
289 higher risk of side effects and adverse events. Although individuals using antithrombotic medications did
290 not demonstrate an elevated risk of ARIA in the trial of lecanemab,³¹ these findings might not apply to
291 non-participants with higher frailty or cardiovascular comorbidity. Moreover, any benefits of monoclonal
292 antibodies against cognitive decline in patients with AD who are at high risk of ischemic stroke, should be
293 carefully weighed against the contraindication for intravenous tissue plasminogen activator in the event
294 of a stroke whilst on monoclonal antibodies against amyloid- β .³² Risk of ARIA is especially high in
295 homozygote *APOE* ϵ 4 carriers, which prompts special consideration for this group in the FDA's

296 appropriate use criteria of lecanemab.^{33,34} In our overall study sample, *APOE* ϵ 4 carriership was
297 somewhat lower than in clinical trials and a prior eligibility study from the U.S.,^{3-5,17} but among those
298 with predicted amyloid positivity, *APOE* ϵ 4 carriership was consistent at around 80%.

299

300 At present, a large number of patients with cognitive impairment defers from seeking medical attention
301 until a fairly advanced stage of the disease. With the clinical availability of medication against AD, it is
302 expected that a substantial number of people with MCI will attend their physician sooner, in the hope of
303 disease-modifying treatment. Adequate preparation is imperative, and includes the necessary
304 diagnostics for determining amyloid status, monitoring safety, and estimating the contribution of
305 amyloid – relative to other contributing causes – to cognitive decline within a single patient.^{35,36} The
306 current study, along with the representative sample of U.S. citizens,¹⁷ offers guidance as to the group of
307 patients for which there is some evidence of treatment efficacy, and those for which there is none as of
308 yet. Even if treatment labels would strictly follow trial eligibility criteria, the absolute number of patients
309 eligible for treatment will pose a challenge to healthcare systems.

310

311 The current study is strengthened by its large, population representative sample with detailed
312 information of demographics, clinical characteristics, and brain imaging. When interpreting our findings,
313 however, some limitations need to be acknowledged. First, brain MRI was available only in a subsample
314 of the Rotterdam Study cohort. The applied prediction algorithm for amyloid positivity may have led to
315 some misclassification of amyloid status. However, the prediction algorithm was derived externally and
316 validation in the Rotterdam Study population (using amyloid-PET) achieved high discriminatory value.²⁸
317 Amyloid-PET is available in a subsample of the Rotterdam Study, but included only seven and thus too
318 few participants with MCI and early dementia to compute meaningful eligibility numbers. Second,
319 operationalization of the eligibility criteria in the Rotterdam Study was at times intrinsically hard to
320 define (e.g., “the participants need to be in good health as determined by the investigator”), or –
321 incidentally– unavailable in the Rotterdam Study (i.e., childbearing potential and sensitivity to PET
322 tracers). Furthermore, availability of an informant/caregiver in the Rotterdam Study might differ from
323 that in clinical practice. Third, we did not include persons who developed dementia within the study
324 period but did not attend the research centre within 1 year from diagnosis. This might have led to some
325 underestimation of ineligibility, as these persons were older and most likely had more comorbid
326 pathology or were “not in good health as determined by the investigator”. Last, the Rotterdam Study

327 consists of a predominantly White population, and generalizability to non-White populations remains to
328 be determined.³⁷

329

330 In conclusion, findings from recent RCTs reporting protective effects of monoclonal antibodies against
331 amyloid- β are applicable to less than 15% of community-dwelling individuals with MCI or early AD. These
332 findings underline that evidence for drug efficacy and safety is still lacking for the majority of patients
333 with AD in the community.

334


335 References

- 336 1. Gauthier S R-NP, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the
337 Diagnosis of Dementia, 2021.
- 338 2. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development
339 pipeline: 2023. *Alzheimers Dement (N Y)* 2023; **9**(2): e12385.
- 340 3. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab
341 in Early Alzheimer's Disease. *J Prev Alzheimers Dis* 2022; **9**(2): 197-210.
- 342 4. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*
343 2023; **388**(1): 9-21.
- 344 5. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The
345 TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *Jama* 2023; **330**(6): 512-27.
- 346 6. FDA Grants Accelerated Approval for Alzheimer's Drug. [https://www.fda.gov/news-events/press-
347 announcements/fda-grants-accelerated-approval-alzheimers-drug](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug) (accessed 02-28 2024).
- 348 7. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval.
349 [https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-
350 treatment-traditional-approval](https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval) (accessed 02-28 2024).
- 351 8. US E. LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer's
352 Disease in Japan 2023. [https://us.eisai.com/press-releases/leqembi-intravenous-infusion-lecanemab-
353 approved-for-the-treatment-of-alzheimers-disease-in-
354 japan#:~:text=%E2%80%9CToday%20LEQEMBI%20received%20approval%2C%20making,of%20the%20di-
355 sease%20in%20Japan](https://us.eisai.com/press-releases/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan#:~:text=%E2%80%9CToday%20LEQEMBI%20received%20approval%2C%20making,of%20the%20disease%20in%20Japan). (accessed 10-09 2023).
- 356 9. Wall JK. Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's
357 Association Conference and Published in JAMA. [https://investor.lilly.com/news-releases/news-release-
358 details/results-lillys-landmark-phase-3-trial-donanemab-presented](https://investor.lilly.com/news-releases/news-release-details/results-lillys-landmark-phase-3-trial-donanemab-presented) (accessed 02-28 2024).
- 359 10. Press release European Medicines Agency accepts Marketing Authorization Application for
360 lecanemab as treatment for early Alzheimer's disease. [https://www.bioarctic.se/en/wp-
361 content/uploads/sites/2/2023/01/bioarctic-european-medicines-agency-accepts-marketing-
362 authorization-application-for-lecanemab-as-t-230126.pdf](https://www.bioarctic.se/en/wp-content/uploads/sites/2/2023/01/bioarctic-european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-t-230126.pdf) (accessed 02-28 2024).
- 363 11. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this
364 trial apply?". *Lancet* 2005; **365**(9453): 82-93.
- 365 12. Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer's dementia attributed to age-
366 related neuropathologies. *Ann Neurol* 2019; **85**(1): 114-24.
- 367 13. Togher Z, Dolphin H, Russell C, Ryan M, Kennelly SP, O'Dowd S. Potential eligibility for
368 Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and
369 appropriate use criteria. *Int J Geriatr Psychiatry* 2022; **37**(8).
- 370 14. Padovani A, Caratozzolo S, Rozzini L, Pilotto A, Benussi A, Tedeschi G. "Real-world" eligibility for
371 aducanumab depends on clinical setting and patients' journey. *J Am Geriatr Soc* 2022; **70**(2): 626-8.
- 372 15. Canevelli M, Rossi PD, Astrone P, Consorti E, Vanacore N, Cesari M. "Real world" eligibility for
373 aducanumab. *J Am Geriatr Soc* 2021; **69**(10): 2995-8.
- 374 16. Anderson TS, Ayanian JZ, Souza J, Landon BE. Representativeness of Participants Eligible to Be
375 Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries
376 With Alzheimer Disease and Mild Cognitive Impairment. *Jama* 2021; **326**(16): 1627-9.
- 377 17. Pittock RR, Aakre J, Castillo AM, et al. Eligibility for Anti-Amyloid Treatment in a Population-
378 Based Study of Cognitive Aging. *Neurology* 2023.

- 379 18. Ikram MA, Brusselle G, Ghanbari M, et al. Objectives, design and main findings until 2020 from
380 the Rotterdam Study. *Eur J Epidemiol* 2020; **35**(5): 483-517.
- 381 19. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. *Arch*
382 *Neurol* 2005; **62**(7): 1160-3; discussion 7.
- 383 20. de Bruijn RF, Akoudad S, Cremers LG, et al. Determinants, MRI correlates, and prognosis of mild
384 cognitive impairment: the Rotterdam Study. *J Alzheimers Dis* 2014; **42 Suppl 3**: S239-49.
- 385 21. Bos D, Vernooij MW, Elias-Smale SE, et al. Atherosclerotic calcification relates to cognitive
386 function and to brain changes on magnetic resonance imaging. *Alzheimers Dement* 2012; **8**(5 Suppl):
387 S104-11.
- 388 22. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information
389 processing speed, executive function and memory. *Brain* 2005; **128**(Pt 9): 2034-41.
- 390 23. Vrooman HA, Cocosco CA, van der Lijn F, et al. Multi-spectral brain tissue segmentation using
391 automatically trained k-Nearest-Neighbor classification. *Neuroimage* 2007; **37**(1): 71-81.
- 392 24. de Boer R, Vrooman HA, van der Lijn F, et al. White matter lesion extension to automatic brain
393 tissue segmentation on MRI. *Neuroimage* 2009; **45**(4): 1151-61.
- 394 25. Andere A, Jindal G, Molino J, et al. Volumetric White Matter Hyperintensity Ranges Correspond
395 to Fazekas Scores on Brain MRI. *J Stroke Cerebrovasc Dis* 2022; **31**(4): 106333.
- 396 26. Joo L, Shim WH, Suh CH, et al. Diagnostic performance of deep learning-based automatic white
397 matter hyperintensity segmentation for classification of the Fazekas scale and differentiation of
398 subcortical vascular dementia. *PLoS One* 2022; **17**(9): e0274562.
- 399 27. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel
400 disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013; **12**(8): 822-38.
- 401 28. Nguyen Ho PT, van Arendonk J, Steketee RME, et al. Predicting amyloid-beta pathology in the
402 general population. *Alzheimers Dement* 2023.
- 403 29. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in
404 Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bmj* 2007; **335**(7624):
405 806-8.
- 406 30. Boyle PA, Wang T, Yu L, et al. To what degree is late life cognitive decline driven by age-related
407 neuropathologies? *Brain* 2021; **144**(7): 2166-75.
- 408 31. Marwan Sabbagh CHvD, Lawrence S, Honig, Jeffrey L, Cummings, Michelle Gee, Michio Kanekiyo,
409 Shobha Dhadd, Michael Irizarry, Lynn D. Krame. LECANEMAB PHASE 3 CLARITY AD TRIAL: ARIA WITH THE
410 USE OF ANTIPLATELETS OR ANTICOAGULANTS in EARLY ALZHEIMER'S DISEASE. 2023.
411 [https://www.bioarctic.se/sv/wp-content/uploads/sites/4/2023/04/ARIA-and-Anticoagulation-](https://www.bioarctic.se/sv/wp-content/uploads/sites/4/2023/04/ARIA-and-Anticoagulation-Antiplatelet-ADPD2023.pdf)
412 [Antiplatelet-ADPD2023.pdf](https://www.bioarctic.se/sv/wp-content/uploads/sites/4/2023/04/ARIA-and-Anticoagulation-Antiplatelet-ADPD2023.pdf) (accessed 02-28 2024).
- 413 32. Reish NJ, Jamshidi P, Stamm B, et al. Multiple Cerebral Hemorrhages in a Patient Receiving
414 Lecanemab and Treated with t-PA for Stroke. *N Engl J Med* 2023; **388**(5): 478-9.
- 415 33. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations.
416 *J Prev Alzheimers Dis* 2023; **10**(3): 362-77.
- 417 34. FDA. Highlights of prescribing information LEQEMBI®.
418 https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf (accessed 2023-
419 12-27 2023).
- 420 35. Belder CRS, Schott JM, Fox NC. Preparing for disease-modifying therapies in Alzheimer's disease.
421 *Lancet Neurol* 2023; **22**(9): 782-3.
- 422 36. van den Berg E, Vernooij MW, Mattace-Raso FUS, Wolters FJ. Sharpening the tools for the
423 assessment of vascular cognitive impairment. *Alzheimers Dement* 2023; **19**(4): 1587-8.
- 424 37. Grill JD, Flournoy C, Dhadda S, et al. Eligibility Rates among Racially and Ethnically Diverse US
425 Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab
426 and Elenbecestat in Early Alzheimer Disease. *Ann Neurol* 2024; **95**(2): 288-98.

428 **Figure 1. Prevalence of trial eligibility criteria among participants with mild cognitive impairment and early Alzheimer’s Disease dementia in**
 429 **the population-based Rotterdam Study**

430 Legend: Trial eligibility criteria among participants with mild cognitive impairment and early Alzheimer’s disease in aducanumab (EMERGE),
 431 lecanemab (CLARITY-AD) and donanemab (TRAILBLAZER-ALZ2) trials. Percentages reflect the percentage of participants with individual eligibility
 432 criterion, or any criterion.



433

434 **Table 1. Eligibility of all 968 participants with mild cognitive impairment and early Alzheimer’s disease dementia in the Rotterdam Study**

	All participants (n=968)	Aducanumab	Lecanemab	Donanemab
No. of participants within trial MMSE range		751	856	762
N (%) eligible based on clinical criteria		178 (23.7)	207 (24.2)	306 (40.2)
Age, mean (SD)	75.1 (8.3)	70.6 (6.7)	74.3 (8.3)	73.2 (6.8)
Women, n (%)	534 (55.2)	90 (50.6)	124 (59.9)	161 (52.6)
MMSE, mean (SD)	25.4 (3.3)	27.1 (1.7)	26.4 (2.2)	25.5 (2.2)
Low educational attainment [^] , n (%)	180 (18.6)	22 (12.4)	40 (19.3)	54 (17.8)
<i>APOE</i> ε4 carriers, n (%)	301 (32.1)	63 (35.6)	55 (27.2)	113 (37.5)
Heterozygote	270 (28.8)	56 (31.6)	50 (24.8)	100 (33.2)
Homozygote	31 (3.3)	7 (4.0)	5 (2.5)	13 (4.3)
Cognitive impairment				
Mild cognitive impairment, n (%)	779 (80.5)	160 (89.9)	178 (86.0)	258 (84.3)
Early dementia, n (%)	189 (19.5)	18 (10.1)	29 (14.0)	48 (15.7)
Cardiovascular disease*, n (%)	266 (27.5)	18 (10.1)	34 (16.4)	56 (18.3)
Antithrombotic medication use, n (%)	392 (40.5)	29 (16.3)	66 (31.2)	103 (33.7)
Antiplatelet	102 (10.5)	19 (10.7)	25 (12.1)	34 (11.1)
Anticoagulant	290 (30.0)	0 (0.0)	41 (19.8)	69 (22.5)

435 Eligibility criteria as applied in the EMERGE trial for aducanumab, CLARITY-AD trial for lecanemab, and TRALBLAZER-ALZ2 trial for donanemab.

436 No., number; MMSE, Mini-Mental State Examination; SD, standard deviation.


437 *indicates composite of previous transient ischemic attack, stroke, myocardial infarction, or coronary artery revascularization procedure.

438 ^indicates primary education only

439 Data were missing for level of education (0.9%) and *APOE* ε4 carriers (3.0%).

440 **Figure 2. Prevalence of trial eligibility criteria among participants with positive predicted amyloid status and mild cognitive impairment or**
 441 **early Alzheimer’s disease dementia in the population-based Rotterdam Study**


442 Trial eligibility criteria among participants with mild cognitive impairment and early Alzheimer’s disease in aducanumab (EMERGE), lecanemab
 443 (CLARITY-AD) and donanemab (TRAILBLAZER-ALZ2) trials. Percentages reflect the percentage of participants with individual eligibility criterion, or
 444 any criterion.



445

446 **Figure 3.**
 447 **Title: Concurrence of eligibility criteria for aducanumab, lecanemab and donanemab**


448 Legend: These intersection diagrams show the patterns of co-occurrence of different eligibility criteria. Rows represent the types of eligibility
 449 criteria and columns represent their combinations. All criteria that are part of a given combination are shown as black dots connected by a
 450 vertical black line. A single dot without a line implies the symptom occurred in isolation. The number of participants with a given combination of
 451 criteria is shown as a vertical bar on top of the matrix. The graph is truncated at a minimum of four participants per combination.



452
 453 BMI indicates body mass index.

454 **Figure 4. Impact of MRI criteria on trial eligibility**

455 Legend: Prevalence of trial eligibility criteria for brain magnetic resonance imaging (MRI) scan among participants with mild cognitive impairment
 456 and Alzheimer’s disease dementia in aducanumab (EMERGE), lecanemab (CLARITY-AD) and donanemab (TRAILBLAZER-ALZ2) trails. Percentages
 457 reflect the percentage of participants with individual eligibility criterion, and MRI abnormalities reflect the presence of any of the MRI criteria.



458
 459 MRI indicates magnetic resonance imaging, WMH indicates white matter hyperintensities.

460 **Table 2. Baseline characteristics for the overall Rotterdam Study cohort with mild cognitive impairment and early Alzheimer’s disease**
 461 **dementia and according to their eligibility for published trials**

	All participants (n=255)	Aducanumab ¹	Lecanemab ²	Donanemab ³
No. of participants with available MRI scan		N = 221	N = 239	N = 209
N (%) eligible based on MRI criteria		158 (71.5)	159 (66.5)	152 (72.7)
N (%) eligible based on clinical + MRI criteria		49 (22.2)	39 (16.3)	64 (30.6)
Age, mean (SD)	74.0 (7.3)	70.0 (6.4)	69.6 (6.7)	71.5 (5.9)
Women, n (%)	113 (44.3)	24 (49.0)	18 (46.2)	29 (45.3)
MMSE, mean (SD)	26.3 (2.4)	26.9 (1.6)	26.9 (1.5)	26.2 (1.8)
Low educational attainment, n (%)	33 (13.0)	6 (12.2)	7 (17.9)	10 (15.6)
<i>APOE</i> ε4 carriers, n (%)	76 (30.6)	19 (38.7)	15 (39.5)	26 (41.3)
Heterozygote	68 (27.4)	17 (34.7)	14 (36.8)	25 (39.7)
Homozygote	8 (3.2)	2 (4.1)	1 (2.6)	1 (1.6)
Cognitive impairment				
Mild cognitive impairment, n (%)	228 (89.4)	45 (91.8)	37 (94.9)	57 (89.1)
Early clinical AD dementia, n (%)	27 (10.6)	4 (8.2)	2 (5.1)	7 (10.9)
Cardiovascular disease [^] , n (%)	74 (29.0)	7 (14.3)	4 (10.3)	8 (12.5)
Antithrombotic medication use, n (%)	113 (44.3)	9 (18.4)	8 (20.5)	10 (16.5)
Antiplatelet	34 (13.3)	9 (18.4)	7 (17.9)	9 (14.1)
Anticoagulant	79 (31.0)	0 (0.0)	1 (2.6)	1 (1.6)

462 ¹ Eligibility criteria as applied in EMERGE trial. ² Eligibility criteria as applied in CLARITY-AD trial. ³ Eligibility as applied in TRALBLAZER-ALZ2 trial.
 463 No., number; MMSE, Mini-Mental State Examination; SD, standard deviation. [^]indicates composite of previous transient ischemic attack, stroke,
 464 myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting. Data were missing for level of education (0.8%)
 465 and *APOE* ε4 carriers (2.7%).